| Document |
Document Title |
|
WO/2023/114822A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
|
WO/2023/109471A1 |
Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
|
|
WO/2023/114539A1 |
The present invention provides novel amino chromen-2-one compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunct...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/104051A1 |
Disclosed is the combined use of an indole substituted tetrahydroisoquinoline compound and a statin compound. Specifically, a safe and non-interaction pharmaceutical composition or pharmaceutical combination. The composition contains an ...
|
|
WO/2023/107722A1 |
This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
|
|
WO/2023/107356A1 |
The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Th...
|
|
WO/2023/107606A1 |
Provided herein are compounds (e.g., compounds of Formula (I) or Formula (II)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds provided here...
|
|
WO/2023/104178A1 |
A series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. Further provided are a pharmaceutical composition containing the compound, and a use of the compound and the pha...
|
|
WO/2023/104213A1 |
The present invention provides a cyclic bisbenzyl tetrahydroisoquinoline compound as represented by formula (I), and a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, a racemate, a crystalline hydrate, and a solvate t...
|
|
WO/2023/106625A1 |
The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/099072A1 |
Compounds of formula (I) wherein Y, n, R1, R2 and R3 have the meanings indicated herein, or a pharmaceutically acceptable solvate or salt thereof, are disclosed. The compounds are useful as inhibitors of protein or lipid kinases (in part...
|
|
WO/2023/102162A1 |
Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):
|
|
WO/2023/098515A1 |
Provided in the present application is a method for preparing a drug-linker conjugate. Specifically, provided in the present application is a method for preparing compound IM2, the method comprising the following steps: adding compound S...
|
|
WO/2023/102378A1 |
The present invention relates to macrocyclic compounds of any one of Formula (I), or a pharmaceutically acceptable form thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating canc...
|
|
WO/2023/101981A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
|
|
WO/2023/102228A1 |
Described herein are compounds of Formula l-A that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
|
|
WO/2023/102231A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...
|
|
WO/2023/097194A2 |
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2023/094304A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/096225A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, and an organic light-emitting device and a composition for forming an organic material layer, comprising same.
|
|
WO/2023/097204A1 |
Microsphere formulations comprising asenapine are provided. Methods for making and using the microsphere formulations are also provided.
|
|
WO/2023/092231A1 |
The invention relates to a pharmaceutical composition comprising a compound ALPHA-1062 or salt thereof, or to a compound ALPHA-1062 or salt thereof, for use in the treatment of confirmed or suspected traumatic brain injury (TBI) in a sub...
|
|
WO/2023/094594A1 |
The present invention relates to substituted dihydropyranopyridines of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their...
|
|
WO/2023/092814A1 |
An amino-substituted chromenoquinoline type fluorescent marker, and a preparation method therefor and the use thereof. The fluorescent marker is prepared by means of subjecting an amino group of an aromatic amine compound and two aldehyd...
|
|
WO/2023/091561A1 |
The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound ...
|
|
WO/2023/088996A1 |
The application relates to crystalline forms of the compound 2'-(7,7- dirnethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1
'-yl)-1,3- dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one (formula I) as well as to processes for the p...
|
|
WO/2023/088235A1 |
The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
|
|
WO/2022/164789A9 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2023/087747A1 |
Disclosed in the present invention are a preparation method for an HIV inhibitor and an intermediate crystalline form thereof. The reaction formula of the HIV inhibitor is as follows. The preparation method of the present invention has h...
|
|
WO/2023/088921A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2023/088493A1 |
The present application provides a furo-pyridone compound and a use thereof. The furo-pyridone compound provided in the present application can selectively inhibit the combination of a BET family bromodomain and acetylated lysine, can be...
|
|
WO/2023/088408A1 |
A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceut...
|
|
WO/2023/088406A1 |
Provided are a fused imide derivative as shown in formula I, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatment of relevant diseases (such as cancers).
|
|
WO/2023/090288A1 |
This organic light-emitting element in which a compound represented by the general formula is used exhibits excellent light-emitting characteristics. R1 represents a hydrogen atom, a deuterium atom, or an alkyl group, R2-R4 each represen...
|
|
WO/2023/085877A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting element comprising same.
|
|
WO/2023/085834A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/085835A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/085860A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2023/085789A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
|
WO/2023/081730A1 |
The present invention relates to 82 specific 4-hydroxy-2-oxo-1,2- dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid CB2 receptor modulators for the treatment of cancer, e.g. to 6-(4- fluorophenyl)-4-hydroxy-1-(2-(4-methy...
|
|
WO/2023/081209A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are PI3K inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/078812A1 |
The present invention relates to dicyano-substituted monoaza- or diazadibenzofurane derivatives and dicyano-substituted monoaza- or diazadibenzothiophene derivatives of the formula (1), wherein the following applies to the symbols and in...
|
|
WO/2023/077910A1 |
The present invention provides a preparation method for a curing agent composition, comprising the following steps: providing a first component and a second component; and mixing the first component and the second component, heating the ...
|
|
WO/2023/079993A1 |
An organic electroluminescent element having excellent properties can be provided by using a compound of the general formula. X represents O or S and R1 to R6 each represent H, D, an alkyl group, or an aryl group. Z1 and/or Z2 is a benzo...
|
|
WO/2023/072945A1 |
Compounds of the formula (I),wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2023/070199A1 |
Methods and corresponding uses are provided for treating disease in a patient, involving the use of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] so as to ameliorate drug resistance, including resistance to proteasome inhibi...
|
|
WO/2023/077070A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
